natgillin/translations-raw huggingface dataset:
In a second study including solid tumours other than breast or prostate cancer, zoledronic acid 4 mg significantly reduced the proportion of patients with an SRE, delayed the median time to first SRE by > 2 months, and reduced the skeletal morbidity rate. 
V drugi študiji, ki je zajela bolnike z drugimi čvrstimi tumorji (razen raka dojke ali prostate) je 4 mg zoledronske kisline značilno zmanjšalo delež bolnikov z enim SRE, podaljšalo mediani čas do prvega
The withdrawn amount of concentrate must be further diluted in 100 ml of sterile 0.9% w/v sodium chloride solution or 5% w/v glucose solution. 
Odvzeto količino koncentrata je treba dodatno redčiti v 100 ml sterilne 0,9% m/v raztopine natrijevega klorida ali 5% m/v raztopine glukoze.
Dizziness, paraesthesia, dysgeusia, hypoaesthesia, hyperaesthesia, tremor, somnolence 
Omotica, parestezije,disgevzija, hipestezija, hiperestezija, tremor, zaspanost Konvulzije, hipestezija in tetanija (zaradi hipokalciemije)
Pruritus, rash (including erythematous and macular rash), increased sweating 
Srbenje, izpuščaj (vključno z eritematoznim in makularnim izpuščajem), močnejše znojenje
Caution is advised when Zoledronic acid Actavis is administered with anti-angiogenic medicinal products, as an increase in the incidence of ONJ has been observed in patients treated concomitantly with these medicinal products. 
Pri uporabi zdravila Zoledronska kislina Actavis skupaj z antiangiogenimi zdravili je potrebna previdnost, saj so pri bolnikih, ki so sočasno prejemali navedena zdravila, opažali povečano pogostnost osteonekroze čeljustnic.
In clinical trials performed in patients with tumour-induced hypercalcaemia (TIH), the overall safety profile amongst all three treatment groups (zoledronic acid 4 and 8 mg and pamidronate 90 mg) was similar in types and severity. 
V kliničnih preskušanjih pri bolnikih s tumorsko povzročeno hiperkalciemijo (TIH) so bile splošne varnostne značilnosti med vsem tremi terapevtskimi skupinami (4 in 8 mg zoledronske kisline oz.
Your doctor may recommend a dental examination before you start treatment with Zoledronic acid Actavis. 
Zdravnik vam bo morda svetoval, da pred začetkom zdravljenja z zdravilom Zoledronska kislina Actavis opravite zobozdravstveni pregled.
• Hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients listed in section 6.1 
• Preobčutljivost za zdravilno učinkovino, za druge difosfonate ali katero koli pomožno snov,
Patients were evenly distributed between zoledronic acid-treated and placebo groups. 
Bolnice so bile enakomerno razdeljene v skupino, ki je prejemala zoledronsko kislino, in skupino, ki je prejemala placebo.
Zoledronic acid 8 mg (N=90) 55.6% (p=0.021)* 83.3% (p=0.010)* 86.7% (p=0.015)* Pamidronate 90 mg (N=99) *p-values compared to pamidronate. 
55,6% (p=0,021)* 83,3% (p=0,010)* 86,7% (p=0,015)*
Zoledronic acid Actavis contains sodium 
Zdravilo Zoledronska kislina Actavis vsebuje natrij
In a third phase III randomised, double-blind trial, 4 mg zoledronic acid or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion. 
V tretjem randomiziranem, dvojno slepem preskušanju III. faze so pri bolnicah/bolnikih z multiplim mielomom ali rakom dojke, ki so imeli vsaj eno kostno lezijo, primerjali 4 mg zoledronske kisline in 90 mg pamidronata na 3 do 4 tedne.
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of Zoledronic acid Actavis along with driving and operating of machinery. 
Neželeni učinki, npr. omotica in zaspanost, lahko vplivajo na sposobnost vožnje in upravljanja s stroji.
Statistically significant differences are marked (*p<0.05) for between treatment comparisons (4 mg zoledronic acid vs. placebo) 
(*p < 0,05) za primerjavo med zdravljenjema (4 mg zoledronske kisline v prim.
Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria Arthritis and joint swelling as a symptom of acute phase reaction 
Astenija, periferni edemi, reakcije na mestu injiciranja (vključno z bolečino, draženjem, oteklostjo, zatrdlino), bolečina v prsih, povečanje telesne mase, anafilaktična reakcija/šok, urtikarija
Common (may affect up to 1 in 10 people): - Headache and a flu-like syndrome consisting of fever, fatigue, weakness, drowsiness, chills and bone, joint and/or muscle ache. 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): - Glavobol in gripi podoben sindrom, ki obsega zvišano telesno temperaturo, utrujenost, šibkost,
Multiple event analysis showed a 36% risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo. 
Analiza multiplih dogodkov je pokazala za 36% manjše tveganje za pojav SRE med prejemniki 4 mg zoledronske kisline v primerjavi s placebom.
Zoledronic acid Actavis treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. 
Pri bolnikih s TIH in hudo okvaro ledvic pride zdravljenje z zdravilom Zoledronska kislina Actavis v poštev šele po oceni tveganj in koristi zdravljenja.
- For storage conditions of Zoledronic acid Actavis after dilution, see “Shelf life after dilution” 
Za pogoje shranjevanja zdravila Zoledronska kislina Actavis po redčenju, glejte “Rok trajanja po redčenju” zgoraj.
Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid. 
Poročali so o poslabšanju delovanja ledvic, napredovanju v ledvično odpoved in dializi po začetnem odmerku ali po enkratnem odmerku 4 mg zoledronske kisline.
Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2-3 days in dogs for up to 52 weeks was also well tolerated. 
Podgane so dobro prenašale tudi do 52-tedensko subkutano uporabo po 0,001 mg/kg/dan, psi pa enako dolgo intravensko dajanje po 0,005 mg/kg enkrat na 2-3 dni.
Other medicines and Zoledronic acid Actavis 
Druga zdravila in zdravilo Zoledronska kislina Actavis
- Zoledronic acid Actavis must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein. 
- Zdravilo Zoledronska kislina Actavis sme dati samo zdravstveni delavec, usposobljen za intravensko dajanje difosfonatov, tj. dajanje difosfonatov v veno.
This medicinal product must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line. 
Tega zdravila se ne sme mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, npr. z raztopino Ringerjevega laktata, in ga je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
One vial with 5 ml concentrate contains 4 mg zoledronic acid (as monohydrate). 
Ena viala s 5 ml koncentrata vsebuje 4 mg zoledronske kisline (kot monohidrata).
The rate of atrial fibrillation serious adverse events was 1.3% (51 out of 3,862) and 0.6% (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. 
Delež atrijske fibrilacije, ki so jo opredelili kot resen neželen dogodek, je bil pri prejemnicah 5 mg zoledronske kisline 1,3% (pri 51 od 3.862 bolnic) in pri prejemnicah placeba 0,6% (pri 22 od 3.852 bolnic).
- Concomitant therapies: chemotherapy, angiogenesis inhibitors (see section 4.5), radiotherapy to neck and head, corticosteroids. 
- sočasna prisotnost raka ali drugih bolezni (na primer anemije, koagulopatije, okužbe), kajenje; - sočasno zdravljenje: kemoterapija, zaviralci angiogeneze (glejte poglavje 4.5), zdravljenje z obsevanjem vratu in glave, kortikosteroidi.
- History of dental disease, poor oral hygiene, periodontal disease, invasive dental procedures 
- Zobozdravstvene bolezni v anamnezi, slaba ustna higiena, peridontalne bolezni, invazivni zobozdravstveni postopki (na primer ekstrakcija zoba) in slabo prileganje protez.
Do not mix Zoledronic acid Actavis concentrate with calcium-containing or other divalent cation containing solutions such as lactated Ringer's solution. 
Koncentrata zdravila Zoledronska kislina Actavis ne smete mešati z raztopinami, ki vsebujejo kalcij ali kakšne druge dvovalentne katione, npr. z raztopino Ringerjevega laktata.
Overhydration should be avoided in patients at risk of cardiac failure. 
Bolniki s tveganjem za srčno popuščanje ne smejo biti prekomerno hidrirani.
• Breast-feeding (see section 4.6) 
navedeno v poglavju 6.1 • Dojenje (glejte poglavje 4.6)
- If you have any further questions, ask your doctor, pharmacist or nurse. 
- Če imate dodatna vprašanja, se posvetujte s svojim zdravnikom, farmcevtom ali z medicinsko sestro.
Efficacy results are provided in Table 2. 
Rezultate učinkovitosti prikazuje Preglednica 2.
The following conventional classification is used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
(≥ 1/100 do <1/10), občasni (≥1/1.000 do < 1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<
One ml concentrate contains 0.8 mg zoledronic acid (as monohydrate). 
En mililiter koncentrata vsebuje 0,8 mg zoledronske kisline (kot monohidrata).
In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been reported in patients that were given zoledronic acid as indicated in sections 4.1 and 4.2. 
Med postmarketinško uporabo so bile pri bolnikih, ki so dobivali zoledronsko kislino, kot je navedeno v poglavjih 4.1 in 4.2, opisane hude bolečine v kosteh, sklepih in/ali mišicah, ki so bolnike v nekaterih primerih povsem onesposobile.
In clinical trials with zoledronic acid, patients with serum creatinine > 265 micromol/l or > 3.0 mg/dl were excluded. 
klinične študije niso vključevali bolnikov s serumskim kreatininom > 265 mikromolov/l ali
No dose adjustment is necessary in TIH patients with serum creatinine < 400 micromol/l or < 4.5 mg/dl (see section 4.4). 
Bolnikom s TIH in serumskim kreatininom < 400 mikromolov/l ali < 4,5 mg/dl odmerka ni treba prilagoditi (glejte poglavje 4.4).
4.0 mg zoledronic acid 3.5 mg* zoledronic acid 3.3 mg* zoledronic acid 3.0 mg* zoledronic acid * Doses have been calculated assuming target AUC of 0.66 (mg•hr/l) (CLcr = 75 ml/min). 
4,0 mg zoledronske kisline 3,5 mg* zoledronske kisline 3,3 mg* zoledronske kisline 3,0 mg* zoledronske kisline
Multiple event analysis showed 30.7% risk reduction in developing SREs in the zoledronic acid 4 mg group compared with placebo. 
Analiza multiplih dogodkov je pokazala za 30,7% manjše tveganje za pojav SRE med prejemniki 4 mg zoledronske kisline kot med prejemniki placeba.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. it is essentially “sodium-free”. 
Zdravilo Zoledronska kislina Actavis vsebuje natrij To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar pomeni, da je praktično "brez natrija".
Discontinuation of bisphosphonate therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment. 
Pri bolnikih s sumom na atipičen zlom stegnenice je treba razmisliti o prenehanju zdravljenja z difosfonatom dokler ni opravljena ocena bolnikovega stanja; pri tem je treba upoštevati individualno oceno koristi in tveganja.
Efficacy results are provided in Table 4. 
Rezultate učinkovitosti prikazuje Preglednica 4.
Clinical trial results in the treatment of severe osteogenesis imperfecta in paediatric patients aged 1 to 17 years 
Pediatrična populacija Rezultati kliničnih preskušanj zdravljenja hude osteogenesis imperfecta pri pediatričnih bolnikih,
The hydration status of patients must be assessed prior to and following administration of Zoledronic acid Actavis to ensure that they are adequately hydrated. 
Pred dajanjem zdravila Zoledronska kislina Actavis in po njem je treba preveriti stanje bolnikove hidracije in tako zagotoviti, da je ustrezno hidriran.
Increases in serum creatinine also occur in some patients with chronic administration of zoledronic acid at recommended doses for prevention of skeletal related events, although less frequently. 
Med kronično uporabo zoledronske kisline v priporočenih odmerkih za preprečevanje z okostjem povezanih dogodkov se lahko zviša kreatinin v serumu, vendar se to zgodi redkeje.
Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. 
Možne neželene učinke zoledronske kisline na plodnost staršev in prve generacije F1 potomcev so ocenjevali na podganah.
- Interstitial lung disease (inflammation of the tissue around the air sacks of the lungs) - Flu-like symptoms including arthritis and joint swelling. 
- Intersticijska bolezen pljuč (vnetje tkiva okoli zračnih mešičkov v pljučih).
Fewer zoledronic acid 4 mg patients suffered pathological fractures. 
Patološke zlome je imelo manj prejemnikov 4 mg zoledronske kisline.
Zoledronic acid Actavis must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line. 
Zdravila Zoledronska kislina Actavis se ne sme mešati z infuzijskimi raztopinami, ki vsebujejo kalcij ali druge dvovalentne katione, na primer z raztopino Ringerjevega laktata, in jo je treba dajati kot samostojno intravensko raztopino z ločenim infuzijskim sistemom.
Hypocalcaemia 
hipokalciemija
One vial contains 4 mg zoledronic acid (as monohydrate). 
Ena viala vsebuje 4 mg zoledronske kisline (kot monohidrata).
Patients should have their serum creatinine levels assessed prior to each dose of Zoledronic acid Actavis. 
Bolnikom je treba pred vsakim odmerkom zdravila Zoledronska kislina Actavis določiti koncentracijo serumskega kreatinina.
During bisphosphonate treatment patients should be advised to report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for an incomplete femur fracture. 
kolku ali dimljah, bolnike, ki imajo takšne simptome, pa je treba oceniti glede nepopolnega zloma stegnenice.
Common (may affect up to 1 in 10 people): - Severe kidney impairment (will normally be determined by your doctor with certain specific blood tests). 
- Huda okvara ledvic (to zdravnik po navadi ugotovi zdravnik z določenimi specifičnimi preiskavami krvi).
- If you get any side effects , talk to your doctor, pharmacist or nurse. 
- Če opazite kateri koli neželeni učinek, se posvetujte s svojim zdravnikom, s farmacevtom ali z medicinsko sestro.
Efficacy results are provided in Table 3. 
Rezultate učinkovitosti prikazuje Preglednica 3.
Patients must be assessed prior to administration of Zoledronic acid Actavis to ensure that they are adequately hydrated. 
Pred uporabo zdravila Zoledronska kislina Actavis je treba bolnike pregledati in tako preveriti, da so ustrezno hidrirani.
Uncommon (may affect up to 1 in 100 people): - Pain in the mouth, teeth and/or jaw, swelling or non-healing sores inside the mouth or jaw, discharge, numbness or a feeling of heaviness in the jaw, or loosening of a tooth. 
- Bolečine v ustih, zobeh in/ali čeljustih, oteklost ali neceljenje ran v ustni votlini ali čeljusti, izcedek, odrevenelost ali občutek teže v čeljusti ali majanje zoba.
Skeletal morbidity rate p-value 
Vrednost p Stopnja obolevnosti skeleta
Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse 
Hipertenzija, hipotenzija, atrijska fibrilacija,
Zoledronic acid 4 mg (N=86) 45.3% (p=0.104) 
Zoledronska kislina 4 mg (N=86)
Single and multiple 5- and 15-minute infusions of 2, 4, 8 and 16 mg zoledronic acid in 64 patients with bone metastases yielded the following pharmacokinetic data, which were found to be dose independent. 
Pri enkratnih in večkratnih 5- in 15-minutnih infundiranjih 2, 4, 8 in 16 mg zoledronske kisline pri
Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth 
mravljinčenje ali omrtvičenost dlani in stopal, driska, zaprtje, bolečine v trebuhu, suha usta.
Warnings and precautions Talk to your doctor before you are given Zoledronic acid Actavis: 
Svojemu zdravniku morate povedati preden dobite zdravilo Zoledronska kislina Actavis :
Renal function impairment 
Okvara delovanja ledvic
EXP Shelf life after dilution: See leaflet. 
Rok uporabnosti po razredčenju: Glejte navodilo.
Other products containing zoledronic acid as active substances are available for osteoporosis indications and treatment of Paget´s disease of the bone. 
Za zdravljenje indikacij pri osteoporozi in za zdravljenje Pagetove bolezni kosti so na voljo druga zdravila, ki kot zdravilno učinkovino vsebujejo zoledronsko kislino.
4.1 ml for 3.3 mg dose 
4,4 ml za odmerek 3,5 mg 4,1 ml za odmerek 3,3 mg 3,8 ml za odmerek 3,0 mg
How often Zoledronic acid Actavis is given 
Kako pogosto se daje zdravilo Zoledronska kislina Actavis
- 4.1 ml for 3.3 mg dose 
- 4,4 ml za odmerek 3,5 mg - 4,1 ml za odmerek 3,3 mg - 3,8 ml za odmerek 3,0 mg
Healthcare professionals are advised not to dispose of unused Zoledronic acid Actavis via the domestic sewage system. 
Neuporabljenega zdravila Zoledronska kislina Actavis se ne sme izliti v gospodinjske odplake.
To assess the effects of 4 mg zoledronic acid versus pamidronate 90 mg, the results of two pivotal multicentre studies in patients with TIH were combined in a pre-planned analysis. 
študijah I. faze za ugotavljanje odmerka pri bolnikih z blago do zmerno hiperkalciemijo, povzročeno s tumorjem (TIH), so bili testirani učinkoviti odmerki v razponu približno 1,2-2,5 mg. Za primerjavo učinkov 4 mg zoledronske kisline in 90 mg pamidronata so v vnaprej načrtovani analizi združili rezultate dveh ključnih multicentričnih študij pri bolnikih s TIH.
What Zoledronic acid Actavis looks like and contents of the pack 
Izgled zdravila Zoledronska kislina Actavis in vsebina pakiranja
<2D barcode carrying the unique identifier included.> <Not applicable.> 
EDINSTVENA OZNAKA - DVODIMENZIONALNA ČRTNA KODA <Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.>
Muscle spasms, osteonecrosis of the jaw Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction) and other anatomical sites including femur and hip 
(neželeni učinek skupine bisfosfonatov) in osteonekroza na drugih anatomskih lokacijah vključno s stegnenico in kolkom
In the clinical trials, renal deterioration was defined as follows: - For patients with normal baseline serum creatinine (< 1.4 mg/dl or < 124 micromol/l), an increase of 0.5 mg/dl or 44 micromol/l; - For patients with abnormal baseline creatinine (> 1.4 mg/dl or > 124 micromol/l), an increase of 
- Pri bolnikih s patološkim izhodiščnim kreatininom (> 1,4 mg/dl ali > 124 mikromolov/l),
- Keep Zoledronic acid Actavis out of the sight and reach of children. 
- Zdravilo Zoledronska kislina Actavis shranjujte nedosegljivo otrokom.
Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing) 
(vključno z utrujenostjo, mrzlico, splošnim slabim počutjem in zardevanjem)
The first randomised, double-blind, placebo-controlled study compared zoledronic acid 4 mg to placebo for the prevention of skeletal related events (SREs) in prostate cancer patients. 
Rezultati kliničnih preskušanj v preprečevanju z okostjem povezanih dogodkov pri bolnikih z napredovalimi malignimi boleznimi, ki zajemajo kosti V prvi randomizirani, dvojno slepi, s placebom kontrolirani študiji so 4 mg zoledronske kisline primerjali s placebom za preprečevanje z okostjem povezanih dogodkov (SRE) pri bolnikih z rakom prostate.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTONS FOR VIALS 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA VIALE
This adverse drug reaction consists of a constellation of symptoms that includes fever, myalgia, headache, extremity pain, nausea, vomiting, diarrhoea, arthralgia and arthritis with subsequent joint swelling. 
Med njenimi simptomi so bolečine v kosteh, zvišana telesna temperatura, utrujenost, artralgija, mialgija, mrzlica in artritis z otekanjem sklepov.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion 
Zoledronska kislina Actavis 4 mg/5 ml koncentrat za raztopino za infundiranje
Reduced levels of calcium in the blood (hypocalcaemia), sometimes leading to muscle cramps, dry skin, burning sensation, have been reported in patients treated with zoledronic acid. 
Pri bolnikih, ki so se zdravili z zdravilom Zoledronska kislina Actavis, so poročali o znižani koncentraciji kalcija v krvi (hipokalciemiji), zaradi katere v nekaterih primerih lahko pride do mišičnih krčev, suhe kože in pekočega občutka.
Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating Zoledronic acid Actavis therapy. 
Po začetku zdravljenja z zdravilom Zoledronska kislina Actavis je treba natančno kontrolirati standardne presnovne parametre, povezane s hiperkalciemijo, npr. serumsko koncentracijo kalcija,
Zoledronic acid Actavis should only be resumed when serum creatinine returns to within 10% of baseline. 
Zdravljenje z zdravilom Zoledronska kislina Actavis se sme znova začeti šele, ko se serumski kreatinin vrne na vrednost, ki je znotraj 10% od izhodiščne vrednosti Zdravljenje z zdravilom Zoledronska kislina Actavis je treba spet začeti z enakim odmerkom, kot ga je bolnik prejemal pred prekinitvijo zdravljenja.
How much Zoledronic acid Actavis is given 
Koliko zdravila Zoledronska kislina Actavis se daje
Rare (may affect up to 1 in 1,000 people): - Slow heart beat. 
Redki (pojavijo se lahko pri 1 od 1.000 bolnikov):
Fractures* 
Zlomi*
- Weight increase. 
- Povečanje telesne mase.
Zoledronic acid Actavis 4 mg/5 ml sterile concentrate zoledronic acid 
Zoledronska kislina Actavis 4 mg/5 ml sterilen koncentrat zoledronska kislina i.v.
How Zoledronic acid Actavis is used 
Kako se uporablja zdravilo Zoledronska kislina Actavis
PHARMACEUTICAL PARTICULARS 6.1 List of excipients 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi manitol natrijev citrat voda za injekcije
Following initiation of therapy, serum creatinine should be measured prior to each dose of Zoledronic acid Actavis and treatment should be withheld if renal function has deteriorated. 
Pred začetkom zdravljenja z zdravilom Zoledronska kislina Actavis je treba izmeriti vrednost kalcija v serumu in odpraviti morebitno hipokalciemijo.
The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear. 
Selektivno delovanje difosfonatov na kost temelji na njihovi veliki afiniteti do mineralizirane kosti,
The results demonstrated that 4 mg zoledronic acid showed comparable efficacy to 90 mg pamidronate in the prevention of SREs. 
SRE podobno učinkovito kot 90 mg pamidronata.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion zoledronic acid 
Zoledronska kislina Actavis 4 mg/5 ml koncentrat za raztopino za infundiranje zoledronska kislina
Uncommon (may affect up to 1 in 100 people): - Hypersensitivity reactions. 
Občasni (pojavijo se lahko pri 1 od 100 bolnikov):
For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. 
O tem, ali prekinitev zdravljenja z difosfonatom zmanjša tveganje za osteonekrozo čeljustnic pri bolnikih, ki potrebujejo zobozdravstvene posege, ni podatkov.
Zoledronic acid Actavis recommended dose* 
Zoledronska kislina Actavis*
Patients must be maintained well hydrated prior to and following administration of Zoledronic acid Actavis. 
Bolniki morajo biti pred dajanjem zdravila Zoledronska kislina Actavis in po njem dobro hidrirani.
Blood creatinine and blood urea increased, hypocalcaemia 
Zvišanje kreatinina in sečnine v krvi,